Dr. DeCoster Eveline, Dermatoloog
ActiveDr. DeCoster Eveline, Dermatoloog has been active since 2019 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €76k and a net result of €40k. Equity is growing by ~2.6% per year across the filed fiscal years. Its solvency ranks better than 67% of 16132 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
Checked score
Score 2025
100
/ 100
Excellent▲ +14 vs 2024
The score combines four axes. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability100=
Solvency100▲+35
Growth52▲+20
Stability100
Bankruptcy probability, 12 months
0.1%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €8k at 30 days acceptable
Liquidity ample (current ratio 4.44 against 1.44 in 2024), and 21.4% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 86
Relative position
BE, all sectors
reference
Sector 86
lower
← fewer bankruptcies
more bankruptcies →
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation dateAge against the risk zone
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
78.6%
Return on assets
41.7%
Age of the figures
8 mo
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 14-07-2026, 17 days ahead of the deadline.
NBB · 6 filingsDeviation from the deadline
2025
17 d early
2024
36 d early
2023
23 d early
2022
11 d early
2021
16 d early
2020
29 d early
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
06-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, micro schema
Equity
€76k▲ 113%
2024 · €36k
2020: €64k
2021: €98k
2022: €119k
2023: €122k
2024: €36k
2020 → 2025
Total assets
€97k▼ 3.7%
2024 · €100k
2020: €134k
2021: €157k
2022: €162k
2023: €141k
2024: €100k
2020 → 2025
Net result
€40k▲ 195%
2024 · €14k
2020: €62k
2021: €34k
2022: €20k
2023: €3k
2024: €14k
2020 → 2025
Working capital
€71k▲ 152%
2024 · €28k
2020: €104k
2021: €122k
2022: €125k
2023: €117k
2024: €28k
2020 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€98k-€119k▲ 20.7%€122k▲ 2.6%€36k▼ 70.8%€76k▲ 113%
Operating result€37k-€28k▼ 24.1%€6k▼ 79.1%€18k▲ 201%€51k▲ 187%
Net result€34k-€20k▼ 40.5%€3k▼ 84.5%€14k▲ 333%€40k▲ 195%
Turnover and EBIT margin not published: the micro schema does not require them.
Result per fiscal year
Operating resultNet result
After the dip in 2023 the operating result has climbed two years in a row; 2025 is 187% above 2024 and is the highest year so far.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €97k
Fixed assets
€5k▼ 35.0%
Current assets
€92k▼ 1.2%
Equity and liabilities €97k
Equity
€76k▲ 113%
Debt
€21k▼ 68.0%
The debt ratio falls from 64.4% to 21.4%: equity grows while debt is paid down.
Key figures and ratios
EBITDA
€54k▲
2024 · €20k
Cash flow
€43k▲
2024 · €16k
Solvency
78.6%▲
2024 · 35.6%
Current ratio
4.44▲
2024 · 1.44
Quick ratio
4.44▲
2024 · 1.44
Debt / equity
0.27▼
2024 · 1.81
ROE
53.0%▲
2024 · 38.3%
ROA
41.7%▲
2024 · 13.6%
Interest coverage
149.19▲
2024 · 37.05
Debt
€21k▼
2024 · €65k
Debt ≤ 1 year
€21k▼
2024 · €65k
Income taxes
€11k▲
2024 · €5k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Total assets
20/58€100k€97k▼
Fixed assets
21/28€7k€5k▼
Tangible fixed assets
22/27€7k€5k▼
Current assets
29/58€93k€92k▼
Amounts receivable within one year
40/41€29k€43k▲
Investments
50/53€11k€17k▲
Cash & bank
54/58€51k€30k▼
Total equity & liabilities
10/49€100k€97k▼
Equity
10/15€36k€76k▲
Contributions / capital
10/11€3k€3k=
Reserves
13€33k€73k▲
Accumulated profits (losses)
14€0€0=
Amounts payable
17/49€65k€21k▼
Amounts payable within one year
42/48€65k€21k▼
Trade debts payable within one year
44€5k€5k▲
Income statement
Code20242025
Gross operating margin
9900€20k€54k▲
Operating result
9901€18k€51k▲
Financial income
75€2k€438▼
Financial charges
65€536€361▼
Result before taxes
9903€19k€51k▲
Income taxes
67/77€5k€11k▲
Net result for the period
9904€14k€40k▲
Result to be appropriated
9905€14k€40k▲
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
14-07
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema
2025
31-12
Financial
Liquidity triplescurrent ratio 4.44
Current ratio from 1.44 to 4.44; short-term debt falls from €65k to €21k.
25-06
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema
2024
08-07
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema
2023
31-12
Financial
Weakest financial yearnet €3k ▼84.5%
Net result drops to €3k, the lowest in the series; recovery starts the following year.
20-07
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema
2022
31-12
Financial
Equity above €100kEq €119k ▲20.7%
3 profitable years in a row build equity to €119k.
15-07
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema
2021
02-07
NBB filing
Annual accounts filed
fiscal year 2020 · micro schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
0 of 1 act read
About the unread acts
We know of 1 Belgian State Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Comparable companies · same sector, comparable size
Similar companies · same sector, comparable size
Dr LEROY JOHANNE
BE 0536.605.384
Nivelles · Eq €76k
Billiet Quatannens
BE 0794.740.596
Jabbeke · Eq €76k
Brussels Skin Center
BE 0739.788.613
Ukkel · Eq €76k
DOCTEUR XAVIER DUNAND
BE 0688.793.634
Grâce-Hollogne · Eq €76k
Docteur Cécile Debabèche
BE 0800.798.148
Liège · Eq €76k
Of 16,586 companies in sector 86220 we hold annual accounts for 7,929. 5,816 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded22-05-2019
Fiscal year end31-12
Activities, NACEBEL
86220Specialist medical practice
86909Human health activities
86995Nutrition and dietetics services
Sources
Crossroads Bank for EnterprisesNational Bank · 6 filingsAddress and cadastre registers
Data from official sources, last processed on 18-07-2026. Scores and ratios are computed by Checked and are not a credit decision.